A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma

Overview of attention for article published in Clinical Cancer Research, October 2008

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
High Attention Score compared to outputs of the same age and source (84th percentile)

Mentioned by

patent: 10 patents

Readers on

mendeley: 87 Mendeley
citeulike: 1 CiteULike

So far, Altmetric has seen 10 patents that reference this research output.

ANTI-GD2 ANTIBODIES

Application EP-4269563-A2

European Patent Office

01 Nov 2023

ANTI-GD2 ANTIBODIES

Application EP-3323830-A1

European Patent Office

23 May 2018

Generation of antibodies to tumor antigens and generation of tumor specific complement…

Grant US-9919047-B2

United States of America

20 Mar 2018

Systemic treatment of metastatic and/or systemically-disseminated cancers using GM-CSF-expr…

Grant US-9180149-B2

United States of America

10 Nov 2015

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity, including 6 additional patents.